{"filing":{"accession_number":"0001299130-26-000117","cik":"0001299130","ticker":"PACB","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-07-30","primary_document":"pacb-20260730.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913026000117/pacb-20260730.htm"},"events":[{"id":24814,"run_id":22500,"accession_number":"0001299130-26-000117","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Pacific Biosciences announced Q2 2026 financial results on August 5, 2026, disclosing total revenue of $39.0 million, gross profit of $12.6 million (GAAP), and a net loss of $44.7 million, with full-year 2026 revenue guidance of $155–$165 million.","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25494,"accession_number":"0001299130-26-000117","item_number":"2.02","item_title":"RESULTS OF OPERATIONS AND FINANCIAL CONDITION.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Pacific Biosciences announced its Q2 2026 financial results on August 5, 2026, disclosing total revenue of $39.0 million, gross profit of $12.6 million (GAAP), and a net loss of $44.7 million. The press release includes detailed financial statements, business highlights, and forward guidance for full-year 2026 revenue of $155–$165 million. This is a standard quarterly earnings release filed under Item 2.02, material to investors assessing the company's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:24:02.892812+00:00","company_name":"","ticker":null,"filing_date":""},{"id":25497,"accession_number":"0001299130-26-000117","item_number":"7.01","item_title":"REGULATION FD DISCLOSURE.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 7.01 discloses a press release relating to leadership changes, but the furnished Exhibit 99.1 is PacBio's Q2 2026 earnings release announcing financial results for the quarter ended June 30, 2026, including revenue of $39.0 million, gross profit, operating expenses, net loss of $44.7 million, and 2026 full-year guidance of $155–$165 million. This is a standard quarterly earnings disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:24:02.892812+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":24815,"run_id":22500,"accession_number":"0001299130-26-000117","anchor_item_number":"2.05","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"The Board approved a restructuring plan on July 30, 2026, involving a reduction in force of approximately 40 employees (8% of workforce) with estimated pre-tax charges of $2.0 million in Q3 2026 for severance, benefits, and outplacement, and targeted annual operating expense reductions of $30–40 million by end of 2027.","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25495,"accession_number":"0001299130-26-000117","item_number":"2.05","item_title":"COSTS ASSOCIATED WITH EXIT OR DISPOSAL ACTIVITIES.","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 2.05 discloses a Board-approved restructuring plan on July 30, 2026, involving a reduction in force of approximately 40 employees (8% of workforce) and operating expense reductions of $30–40 million annually by end of 2027, with estimated pre-tax charges of $2.0 million in Q3 2026 for severance, benefits, and outplacement. This is a classic workforce reduction event with associated exit costs, directly matching the `workforce_reduction` taxonomy category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:24:02.892812+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":24816,"run_id":22500,"accession_number":"0001299130-26-000117","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Mark Van Oene was appointed as President and Chief Executive Officer and Board member effective August 5, 2026, succeeding Christian Henry who stepped down from the CEO role, with a compensation package including a base salary of $743,000, target bonus of 100%, stock options worth $1,687,500, and RSUs worth $562,500.","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25496,"accession_number":"0001299130-26-000117","item_number":"5.02","item_title":"DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Mark Van Oene was appointed as President and Chief Executive Officer and Board member effective August 5, 2026, succeeding Christian Henry who stepped down from the CEO role. While the disclosure includes compensatory arrangements (base salary of $743,000, target bonus of 100%, stock options worth $1,687,500, and RSUs worth $562,500), the principal disclosed action is the appointment of a new CEO to a leadership position. The appointment of a CEO is a material governance event affecting investor assessment of company leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:24:02.892812+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25494,"accession_number":"0001299130-26-000117","item_number":"2.02","item_title":"RESULTS OF OPERATIONS AND FINANCIAL CONDITION.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Pacific Biosciences announced its Q2 2026 financial results on August 5, 2026, disclosing total revenue of $39.0 million, gross profit of $12.6 million (GAAP), and a net loss of $44.7 million. The press release includes detailed financial statements, business highlights, and forward guidance for full-year 2026 revenue of $155–$165 million. This is a standard quarterly earnings release filed under Item 2.02, material to investors assessing the company's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:24:02.892812+00:00","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","filing_date":"2026-08-05"},{"id":25495,"accession_number":"0001299130-26-000117","item_number":"2.05","item_title":"COSTS ASSOCIATED WITH EXIT OR DISPOSAL ACTIVITIES.","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 2.05 discloses a Board-approved restructuring plan on July 30, 2026, involving a reduction in force of approximately 40 employees (8% of workforce) and operating expense reductions of $30–40 million annually by end of 2027, with estimated pre-tax charges of $2.0 million in Q3 2026 for severance, benefits, and outplacement. This is a classic workforce reduction event with associated exit costs, directly matching the `workforce_reduction` taxonomy category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:24:02.892812+00:00","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","filing_date":"2026-08-05"},{"id":25496,"accession_number":"0001299130-26-000117","item_number":"5.02","item_title":"DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Mark Van Oene was appointed as President and Chief Executive Officer and Board member effective August 5, 2026, succeeding Christian Henry who stepped down from the CEO role. While the disclosure includes compensatory arrangements (base salary of $743,000, target bonus of 100%, stock options worth $1,687,500, and RSUs worth $562,500), the principal disclosed action is the appointment of a new CEO to a leadership position. The appointment of a CEO is a material governance event affecting investor assessment of company leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:24:02.892812+00:00","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","filing_date":"2026-08-05"},{"id":25497,"accession_number":"0001299130-26-000117","item_number":"7.01","item_title":"REGULATION FD DISCLOSURE.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 7.01 discloses a press release relating to leadership changes, but the furnished Exhibit 99.1 is PacBio's Q2 2026 earnings release announcing financial results for the quarter ended June 30, 2026, including revenue of $39.0 million, gross profit, operating expenses, net loss of $44.7 million, and 2026 full-year guidance of $155–$165 million. This is a standard quarterly earnings disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:24:02.892812+00:00","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","filing_date":"2026-08-05"}]}